Jacob Chacko was most recently CFO of Ignyta, a NASDAQ-listed precision oncology company acquired by Roche in February 2018. At Ignyta, he had a broad operational role and helped raise over $500 million in capital. During his tenure, the company grew from fewer than 20 employees and a $50 million enterprise value to 125 employees and a $1.7 billion enterprise value at the time of acquisition. Prior to Ignyta, Chacko was an investor at TPG Capital, where he helped lead teams that completed acquisitions having an aggregate value of over $10 billion. He has served on the board of directors of Bonti, RentPath and EnvisionRx and was a board observer to Par Pharmaceutical, IMS Health and Quintiles Transnational. He previously served on the board of the Packard Children’s Health Alliance at the Lucile Packard Children’s Hospital Stanford.Chacko concurrently received his MD with AOA honors from UCLA and his MBA with Distinction from Harvard Business School. Prior to that, he was a consultant serving healthcare clients at McKinsey & Company. He received a MSc from Oxford University as a Marshall Scholar and undergraduate degrees from the University of Southern California, where he graduated as the University Valedictorian. He currently serves on the board of directors of Turning Point Therapeutics and chairs the Western Regional Selection Committee for the Marshall Scholarship.
Organization Name | Title At Company | Start Date | End Date | |
---|---|---|---|---|
ORIC Pharmaceuticals | President & Chief Executive Officer | Apr 1, 2018 | — | Detail |
ORIC Pharmaceuticals | Board Member | — | — | Detail |